{"groups":[{"description":"Alisertib was administered PO at 50 mg BID for 7 days in each treatment cycle, followed by a 14-day, treatment-free period, for a 21-day cycle.","id":"FG000","title":"Alisertib"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"17"}],"type":"Progression"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"26"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"26"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"28 participants signed consent, 2 participants inevaluable.","recruitmentDetails":"Recruitment Period: May 2015 - February 2017. The patients were recruited in the Thoracic clinic at MD Anderson Cancer Center."}